The osteonecrosis treatment market size is projected to be valued at USD 268.2 million in 2023 and is expected to rise to USD 434.0 million by 2033. The sales of osteonecrosis treatment are expected to expand at a significant CAGR of 4.9% during the forecast period.
Osteonecrosis generally occurs in shoulder joints, hip joints, knee joints, and ankle joints. Osteonecrosis is of two types, viz., non-traumatic osteonecrosis and traumatic osteonecrosis. It can be an outcome of reduced blood supply because of a fracture, alarming use of chronic corticosteroids, bone dislocation, and alcohol addiction.
An important factor responsible for the osteonecrosis treatment market growth is an increase in alcohol consumption across the world. The National Institute on Alcohol Abuse and Alcoholism conducted a study and concluded that in the past few years, the number of individuals consuming alcohol has exponentially grown in the United States. Further, the osteonecrosis treatment market study also mentions that the number of female alcohol consumers has doubled.
Alcohol abuse results in abnormal lipid metabolism and this is a significant risk factor for alcohol induces osteonecrosis and leading to a surge of osteonecrosis treatment market key trends and opportunities.
There is an increasing prevalence of osteonecrosis, as there are a few reasons that cause this medical condition is common. Therefore, the demand for osteonecrosis treatment is surging and the osteonecrosis treatment market’s future trends are said to expand exponentially during the forecast period.
| Attributes | Details |
|---|---|
| Osteonecrosis Treatment Market Estimated Size (2023) | USD 268.2 million |
| Osteonecrosis Treatment Market CAGR (2023 to 2033) | 4.9% |
| Osteonecrosis Treatment Market Forecasted Size (2033) | USD 434.0 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Geriatric Population Growth
The increasing geriatric population is leading to a rise in hip injuries and this is promoting the osteonecrosis treatment market during the forecast period. Further, hip injuries such as degeneration or fractures may result in obstructed blood flow to the bone, leading to trauma-related osteonecrosis and boosting the osteonecrosis treatment adoption trends.
Alarming cases of traumatic injuries and road accidents coupled with excessive consumption of alcohol across the world are anticipated to promote the osteonecrosis treatment market growth. Further, the consumption of corticosteroids excessively also favors the demand for osteonecrosis treatment and therefore surging the sales of osteonecrosis treatment.
Biotechnology Companies
Several measures are taken by biotechnology companies focusing on the development of new treatment options for individuals experiencing osteonecrosis. This is propelling the global osteonecrosis treatment options escalating the osteonecrosis treatment market future trends.
Great Recognition of Non-Invasive Treatment
The demand for osteonecrosis treatment is said to escalate due to rising awareness about non-invasive methods of osteonecrosis treatment. Since this medical condition is asymptomatic and idiopathic in nature, it is increasing the burden on the patient population and is also linked to individuals of any age group.
When osteonecrosis is left untreated, it leads to several complications and therefore there is a high demand for osteonecrosis treatment. This is a core osteonecrosis treatment market driving factor.
Research and Development Activities
The osteonecrosis treatment market opportunities will surge owing to a great number of research and development activities for developing novel drugs. Additionally, technological advancements for enhanced osteonecrosis treatment coupled with increasing demand for non-invasive treatment are some of the other crucial osteonecrosis treatment market driving factors.
Facets Barring the Osteonecrosis Treatment Market
Allocation of Alternative Ways
The main goal after being diagnosed with any disease is to get the condition treated as soon as possible to avoid the progression of osteonecrosis symptoms. As a result, the available treatment is expected to significantly decelerate the osteonecrosis treatment market growth.
NSAIDs are a class of medications commonly used to reduce inflammation and relieve pain. In the context of osteonecrosis. NSAIDs are often prescribed to manage pain and reduce inflammation in affected joints.
In the treatment of osteonecrosis, NSAIDs are typically used as part of a comprehensive management plan that may also include other interventions, such as physical therapy, lifestyle modifications, and in some cases, surgical interventions. Also, the specific NSAID prescribed and the duration of treatment may vary depending on the individual patient and the severity of their condition.
Osteonecrosis is a complex condition that requires specialized medical care, including diagnosis, treatment, and follow-up monitoring. Hospitals play a crucial role in providing comprehensive healthcare services to patients with osteonecrosis.
Hospitals provide a range of treatment options for osteonecrosis, depending on the stage and severity of the disease. These treatments may include conservative measures such as pain management, physical therapy, and lifestyle modifications. Further, in more advanced cases, surgical interventions, such as joint-preserving procedures or joint replacement surgeries, may be performed.
Hospitals serve as centers for research and innovation in osteonecrosis treatment. They contribute to the development of new treatment modalities, clinical trials, and advancements in surgical techniques aimed at improving patient outcomes.
Principal Consultant
The drug segment has a considerable osteonecrosis treatment market share and is said to be in demand for osteonecrosis treatment during the forecast period owing to being extremely efficient, having fewer side effects as compared to other therapies, and non-invasive nature.
North America is said to be accountable for a significant revenue share as it holds 37.8% osteonecrosis treatment market share due to the high adoption of advanced treatment options and concentration of key osteonecrosis treatment market manufacturers. High adoption of osteonecrosis treatment methods is witnessed in the United States.
The increasing geriatric population coupled with growing awareness of the medical condition and the diagnosis of the same amongst people in this region is said to boost the osteonecrosis treatment market growth. With an increasing number of inorganic growth strategies by market players, North America is anticipated to dominate its position in the osteonecrosis treatment market.
Europe is said to hold a 31.3% osteonecrosis treatment market share. This region portrays a high growth rate owing to the increasing number of surgical procedures such as joint replacements. Increasing healthcare expenditure and the rising number of bone disorders are also responsible for the osteonecrosis treatment market growth in Europe.
The presence of well-established healthcare infrastructure, technological advancements, and the launch of novel drugs and treatment options for osteonecrosis are also propelling the osteonecrosis treatment market growth in Europe.
China is to Witness a 5.9% CAGR during the Analysis Period.
Healthcare providers and researchers in the country are actively involved in developing and implementing innovative treatments for osteonecrosis. China's robust healthcare infrastructure and advancements in medical technology provide a favorable environment for the growth of the osteonecrosis treatment market. Further, the country is witnessing advancements in diagnostic techniques, surgical procedures, and regenerative therapies aimed at improving patient outcomes and preserving joint function.
The government of China focuses on healthcare reforms, investments in research and development, and the availability of skilled healthcare professionals to contribute to the development and adoption of effective treatment strategies for osteonecrosis.
The competitive landscape in the osteonecrosis treatment market is characterized by the presence of several key players and a competitive environment. These players are actively engaged in research and development activities, strategic collaborations, mergers and acquisitions, and product launches to strengthen their market position and gain a competitive edge.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.9% from 2023 to 2033 |
| Base Year of Estimation | 2023 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD billion and Volume in Units and F-CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis |
| Key Segments Covered | Drug Type, Therapy, End User, By Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; The Middle East & Africa; Oceania |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, Italy, France, The United Kingdom, Spain, Russia, China, Japan, India, GCC Countries, Australia |
| Key Companies Profiled | Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; Bone Therapeutics SA; Mylan NV; Regrow Biosciences; Vericel Corporation; Zimmer Biomet; Enzo Biochem Inc. |
| Customization & Pricing | Available upon Request |
The market is expected to generate revenue of USD 268.2 million in 2023.
The market is set to expand at a CAGR of 4.9% in the forecast period.
The anticipated remuneration of the market is USD 434.0 million by 2033.
Rising geriatric population and growing awareness about non-invasive treatment are increasing the product sales.
Insufficient awareness and expensive rate of this treatment are holding back the market growth.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. NSAIDS 5.2. Cholesterol-Lowering Drugs 5.3. Blood Thinners 5.4. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 6.1. Stem Cell Therapy 6.2. Joint Replacement Surgery 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Homecare 7.3. Specialty Clinics 7.4. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Pfizer Inc. 18.2. Merck & Co. Inc. 18.3. Novartis AG 18.4. Teva Pharmaceutical Industries Ltd 18.5. Bone Therapeutics SA 18.6. Mylan NV 18.7. Regrow Biosciences 18.8. Vericel Corporation 18.9. Zimmer Biomet 18.10. Enzo Biochem Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Osteonecrosis Treatment Market
